Andreas F. Borkenstein, MD, discusses a unique device in the fight against dry age-related macular degeneration.
A new class of IOL technology (EyeMax Mono) is tailored for patients with dry age-related macular degeneration (AMD). By optimising image quality available across the macula, the device maximises the use of a preferred retinal locus (PRL) to improve vision function without the need for visual rehabilitation.
AMD is the leading cause of blindness worldwide. Currently, there are no treatments for dry AMD, a debilitating form of the disease in which patients experience slow and progressive loss of visual function and quality of life.1
As the world’s ageing population continues to grow, global AMD prevalence is also expected to increase. Andreas F. Borkenstein, MD is an ophthalmologist working in Austria. He notes that while several effective therapies are available for his patients with wet AMD, no cure exists for dry AMD and that a ‘wait-and-see’ approach can be very frustrating for the patient and ophthalmic surgeon.
Dry AMD accounts for approximately 85–90% of all AMD cases.2 For these patients, the current recommended standard of care is limited to lifestyle changes (e.g., smoking cessation), the use of low-vision magnification aids and undertaking intensive training to use their peripheral vision.
“For many older individuals,” says Dr Borkenstein, “a diagnosis of dry AMD is associated with fear that they will spend their sunset years in complete blindness and being entirely dependent on others.”
Dry AMD involves the degeneration of the pigmented epithelial layer of the retina. Patients may also have drusen in the macula that can grow in size, shape and change in distribution over time. This ultimately results in patients having gaps in their central vision, which impacts reading and daily activities. It is estimated that at least a quarter of patients requiring cataract surgery will also have intermediate or advanced AMD, presenting the opportunity for targeted IOL implantation in appropriate patients.
Andreas F. Borkenstein, MD
Dr Borkenstein is a consultant ophthalmic surgeon in the Privatklinik der Kreuzschwestern in Graz, Austria, and co-owner of Borkenstein & Borkenstein. Writing assistance for this article was provided by Linda Shi and David Da Costa from Syneos Health Communications; the funding for this was provided by LEH Pharma.
1. Schmidt-Erfurth U, et al. Ophthalmology 2014;121:193–201
2. Chandramohan A, et al. Retina 2016;36:1021–31
3. Huynh N, et al. Ophthalmology 2014;121:1229–36
4. Robbie SJ, et al. J Refract Surg 2018;34:718–25
5. Borkenstein AF and Borkenstein E-M. Medicine 2019;98:e16583 (DOI: http://dx.doi.org/10.1097/MD.0000000000016583)
6. Borkenstein AF and Borkenstein E-M. Poster presented at American Society of Cataract and Refractive Surgery Annual Meeting 2019 (Poster 53377)
7. Badala F, et al. Poster presented at the American Academy of Ophthalmology’s Annual Meeting 2018 (Poster PO013)
8. Qureshi MA, et al. Eur J Ophthalmol 2018;28:198–203.